Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers

Exclusion Criteria

• •Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.
• •Planned participation in another clinical trial during the present trial period.
• •Receipt of any vaccine in the 4 weeks preceding the first trial vaccination except for pandemic influenza vaccination, which may be received at least two weeks before the study vaccines.
• •Planned receipt of any vaccine up to the 6 weeks following the last trial vaccination except for pandemic influenza vaccine. In the event of a local or national immunization program with a pandemic influenza vaccine, participants who receive a pandemic influenza vaccine at any time during the trial will not be withdrawn from the trial.
• •Previous vaccination against measles, measles-mumps-rubella (MMR), or flavivirus disease, including Japanese encephalitis (JE).
• •Receipt of blood in the past 6 months that might interfere with the assessment of the immune response
• •Receipt of intravenous injection of plasma, platelet product, or high dose of intravenous immunoglobulin in the past 11 months
• •Receipt of intramuscular treatment of immunoglobulin or Hepatitis B immunoglobulin in the past 3 months
• •Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.
• •Known history of human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C seropositivity.
• •History of measles, mumps, rubella, or flavivirus infection confirmed either clinically, serologically, or microbiologically.
• •Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing any of the same substances .
• •Known systemic hypersensitivity to gelatin, eggs, or anaphylactic/anaphylactoid reaction to neomycin.
• •Known history of thrombocytopenia.
• •Administration of any anti-viral within 2 months preceding first vaccination and up to the 6 weeks following the last trial vaccination.
• •History of central nervous system disorder or disease, including seizures and febrile seizures.
• •Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.